HC Wainwright Comments on LifeMD's Q1 Earnings (NASDAQ:LFMD)

Key Points

• HC Wainwright has revised down its Q1 2026 earnings estimate for LifeMD to $0.05 per share, decreasing from a previous estimate of $0.06, while maintaining a "Buy" rating and a price target of $13.00.
• Lake Street Capital has also cut its price target for LifeMD from $18.00 to $14.00 and downgraded the stock to a "buy" rating, while other analysts have varied in their ratings, resulting in a consensus rating of "Moderate Buy".
• LifeMD's stock is currently trading at $6.83, with a 52-week range of $3.99 to $15.84, indicating volatility and potentially offering a buying opportunity based on market sentiment.

LifeMD, Inc. (NASDAQ:LFMD - Free Report) - Analysts at HC Wainwright reduced their Q1 2026 earnings per share (EPS) estimates for shares of LifeMD in a research report issued to clients and investors on Thursday, August 7th. HC Wainwright analyst Y. Chen now anticipates that the company will earn $0.05 per share for the quarter, down from their prior forecast of $0.06. HC Wainwright currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for LifeMD's current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for LifeMD's Q2 2026 earnings at $0.09 EPS, Q3 2026 earnings at $0.13 EPS, Q4 2026 earnings at $0.20 EPS and FY2026 earnings at $0.47 EPS.

A number of other brokerages have also weighed in on LFMD. BTIG Research increased their target price on LifeMD from $15.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday, June 18th. Wall Street Zen lowered LifeMD from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. KeyCorp lowered their target price on LifeMD from $14.00 to $12.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 6th. Finally, Lake Street Capital cut their price objective on shares of LifeMD from $18.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $12.86.

LifeMD Stock Performance

LifeMD stock traded up $0.11 during mid-day trading on Friday, hitting $6.83. 2,621,004 shares of the company's stock traded hands, compared to its average volume of 1,671,861. The company has a debt-to-equity ratio of 9.21, a current ratio of 0.77 and a quick ratio of 0.72. The firm has a 50 day simple moving average of $11.74 and a two-hundred day simple moving average of $8.53. LifeMD has a fifty-two week low of $3.99 and a fifty-two week high of $15.84. The stock has a market cap of $323.88 million, a price-to-earnings ratio of -32.52 and a beta of 1.72.

Institutional Investors Weigh In On LifeMD

Several hedge funds and other institutional investors have recently modified their holdings of LFMD. Nisa Investment Advisors LLC lifted its stake in shares of LifeMD by 148.5% in the second quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company's stock valued at $50,000 after buying an additional 2,185 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of LifeMD by 1,004.9% in the second quarter. Caitong International Asset Management Co. Ltd now owns 5,171 shares of the company's stock valued at $70,000 after buying an additional 4,703 shares in the last quarter. GAMMA Investing LLC bought a new position in shares of LifeMD in the first quarter valued at $35,000. CWM LLC lifted its stake in shares of LifeMD by 17.5% in the first quarter. CWM LLC now owns 9,050 shares of the company's stock valued at $49,000 after buying an additional 1,351 shares in the last quarter. Finally, Baader Bank Aktiengesellschaft bought a new position in shares of LifeMD in the second quarter valued at $136,000. Institutional investors own 35.52% of the company's stock.

Insider Activity at LifeMD

In other LifeMD news, CEO Justin Schreiber sold 25,000 shares of the company's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $13.38, for a total value of $334,500.00. Following the completion of the transaction, the chief executive officer directly owned 2,500,721 shares in the company, valued at approximately $33,459,646.98. This represents a 0.99% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Eric Harold Yecies sold 15,000 shares of the company's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $12.25, for a total transaction of $183,750.00. Following the completion of the transaction, the insider owned 16,100 shares of the company's stock, valued at approximately $197,225. This trade represents a 48.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 275,000 shares of company stock valued at $3,564,550 in the last quarter. 18.40% of the stock is owned by company insiders.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.